Comment Comment by eatbitseveryday NYTimes also covers the story (https://www.nytimes.com/2017/07/12/health/fda-novartis-leuke...) with more discussion about individual patients.From the NYT article:> The panel recommended approving the treatment for B-cell acute lymphoblastic leukemia that has resisted treatment, or relapsed, in children and young adults aged 3 to 25.Why so young? parent eatbitseveryday 9 years ago
From the NYT article:
> The panel recommended approving the treatment for B-cell acute lymphoblastic leukemia that has resisted treatment, or relapsed, in children and young adults aged 3 to 25.
Why so young?